The Health Canada has approved a label change for Biogen Idec's Tysabri to include anti-JC virus (JCV) antibody status as a risk factor for patients with multiple sclerosis (MS). The product monograph change will help enable ...
Tags: label change, Health Canada, risk assessment
Biogen Idec (BIIB) and Isis Pharmaceuticals have entered into an exclusive, worldwide option and collaboration agreement, pursuant to which the companies will develop and commercialize a novel antisense drug for the treatment of myotonic ...
Tags: Steinert Disease, antisense drug